IOVA vs. RARE
Compare and contrast key facts about Iovance Biotherapeutics, Inc. (IOVA) and Ultragenyx Pharmaceutical Inc. (RARE).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: IOVA or RARE.
Key characteristics
| IOVA | RARE | |
|---|---|---|
| YTD Return | 25.09% | 20.66% |
| 1Y Return | 87.29% | 58.56% |
| 3Y Return (Ann) | -26.42% | -16.30% |
| 5Y Return (Ann) | -13.49% | 6.29% |
| 10Y Return (Ann) | 4.10% | 0.53% |
| Sharpe Ratio | 0.76 | 1.21 |
| Daily Std Dev | 93.68% | 48.70% |
| Max Drawdown | -99.36% | -82.11% |
| Current Drawdown | -93.60% | -67.47% |
Fundamentals
| IOVA | RARE | |
|---|---|---|
| Market Cap | $3.16B | $5.32B |
| EPS | -$1.67 | -$7.21 |
| PEG Ratio | 0.00 | -0.24 |
| Total Revenue (TTM) | $32.77M | $481.30M |
| Gross Profit (TTM) | -$34.93M | $401.75M |
| EBITDA (TTM) | -$428.77M | -$507.15M |
Correlation
The correlation between IOVA and RARE is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
IOVA vs. RARE - Performance Comparison
In the year-to-date period, IOVA achieves a 25.09% return, which is significantly higher than RARE's 20.66% return. Over the past 10 years, IOVA has outperformed RARE with an annualized return of 4.10%, while RARE has yielded a comparatively lower 0.53% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
IOVA vs. RARE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and Ultragenyx Pharmaceutical Inc. (RARE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
IOVA vs. RARE - Dividend Comparison
Neither IOVA nor RARE has paid dividends to shareholders.
Drawdowns
IOVA vs. RARE - Drawdown Comparison
The maximum IOVA drawdown since its inception was -99.36%, which is greater than RARE's maximum drawdown of -82.11%. Use the drawdown chart below to compare losses from any high point for IOVA and RARE. For additional features, visit the drawdowns tool.
Volatility
IOVA vs. RARE - Volatility Comparison
Iovance Biotherapeutics, Inc. (IOVA) has a higher volatility of 18.93% compared to Ultragenyx Pharmaceutical Inc. (RARE) at 9.45%. This indicates that IOVA's price experiences larger fluctuations and is considered to be riskier than RARE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
IOVA vs. RARE - Financials Comparison
This section allows you to compare key financial metrics between Iovance Biotherapeutics, Inc. and Ultragenyx Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities